Belzutifan, XmAbA 808, XL092, VB10.NEO, Savolitinib, RC198, NKT2152, NGM707, MEDI5752, ADI-270, ALLO 316, KO 2806, TT-10, Fruquintinib, AB 2100,and others are under different phases of advan...
Advanced kidney cancer (RCC) View all clinical trials KEYTRUDA+ axitinib helped patientslive longercompared to sunitinib A clinical trial compared patients with advanced renal cell carcinoma who received KEYTRUDA, an immunotherapy, in combination with axitinib, a tyrosine kinase inhibitor (TKI), to thos...
CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer....
kidneyrenal carcinomasunitinibtemsirolimusinterferon alfa 2aErratum in JAMA. 2007 Apr 25;297(16):1774.doi:10.1001/jama.296.2.155HamptonTracyJAMAJamaHampton T. Trials probe new agents for kidney cancer. JAMA 2006;296:155-7.Hampton T. Trials probe new agents for kidney cancer. JAMA 2006;296:155...
In our field, genitourinary oncology, we have some preliminary compelling evidence in bladder cancer. If you look at ctDNA, you could stratify patients who are the highest risk for metastatic recurrence, and maybe give them adjuvant chemotherapy. We have some ongoing clinical trials, like th...
In recent decades, variability in the incidence and mortality of kidney cancer (KC) has been reported. This study aimed to compare trends in incidence, mortality, and disability-adjusted life years (DALY) of KC between the European Union (EU) 15 + countries and 6 World Health Organization...
The analysis of data from the selected studies reported inTables 2and3provides information on how the features of renal cancer have evolved over the years and why some unexpected results have been observed in clinical trials. How have the disease features evolved?
The next step, Thomas said, is initiating clinical trials to test how these tumors respond to drugs already available and approved by the FDA. There are many implications for the Src findings. Last year alone, kidney cancer accounted for about 58,000 new cases of cancer and 13,000 deaths ...
Patrick Ott, MD, Ph.D., director of the Center for Cancer Vaccines at Dana-Farber, and Derin Keskin, Ph.D., immunologist at the Center for Cancer Vaccines at Dana-Farber, are also co-senior authors. David A. Braun, MD, Ph.D., formerly of Dana-Farber and Harvard Medical School, and...
Dynamic Contrast-enhanced MR Imaging of Kidney Cancer in Angiogenic Inhibitor Trials LEARNING OBJECTIVES 1) The principles of angiogenesis in the development of malignant tumors, and the relationship of VEGF signaling to tumorigenesis in RC... MA Rosen - Radiological Society of North America Scientific...